GlucoTrack, Inc. (GCTK)
NASDAQ: GCTK · Real-Time Price · USD
0.330
-0.001 (-0.30%)
At close: Jun 26, 2026, 4:00 PM EDT
0.320
-0.010 (-3.03%)
After-hours: Jun 26, 2026, 7:56 PM EDT
Company Description
GlucoTrack, Inc., a medical device company, focuses on the development of an implantable continuous blood glucose monitor (CBGM) for people with diabetes in the United States.
The company develops the GlucoTrack CBGM, a long-term implantable blood-based CBGM for use by Type 1 diabetes patients and insulin-dependent Type 2 diabetes patients.
The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021.
GlucoTrack, Inc. was founded in 2001 and is based in Rutherford, New Jersey.
GlucoTrack, Inc.
| Country | United States |
| Founded | 2001 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 15 |
| CEO | Paul Goode |
Contact Details
Address: 301 Route 17 North, Suite 800 Rutherford, New Jersey 07070 United States | |
| Phone | 201 842 7715 |
| Website | glucotrack.com |
Stock Details
| Ticker Symbol | GCTK |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001506983 |
| CUSIP Number | 45824Q804 |
| ISIN Number | US45824Q8042 |
| Employer ID | 98-0668934 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Dr. Paul V. Goode Ph.D. | Chief Executive Officer, President and Director |
| Avner Gal MBA, MSc.EE | Co-Founder, Chairman Emeritus, Consultant and Member of Scientific and Clinical Advisory Board |
| David Malka BA | Co-Founder |
| Vincent Wong | Chief Operations Officer |
| Dr. Mark Tapsak Ph.D. | Chief Scientific Officer |
| Drinda Benjamin | Vice President of Marketing |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 17, 2026 | PRE 14A | Other preliminary proxy statements |
| May 15, 2026 | 8-K | Current Report |
| May 15, 2026 | SCHEDULE 13G/A | Filing |
| May 14, 2026 | 10-Q | Quarterly Report |
| May 14, 2026 | 8-K | Current Report |
| May 7, 2026 | 8-K | Current Report |
| Apr 30, 2026 | EFFECT | Notice of Effectiveness |
| Apr 30, 2026 | 8-K | Current Report |
| Apr 30, 2026 | 8-K | Current Report |
| Apr 29, 2026 | POS AM | Post-Effective amendments for registration statement |